VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNE) will likely be issuing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter. Parties may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Monday, November 10, 2025 at 12:30 PM ET.

VYNE Therapeutics (NASDAQ:VYNE) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.10. VYNE Therapeutics had a negative net margin of 8,097.69% and a negative return on equity of 77.57%. The company had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.15 million. On average, analysts expect VYNE Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

VYNE Therapeutics Stock Down 2.7%

Shares of VYNE Therapeutics stock opened at $0.35 on Tuesday. VYNE Therapeutics has a 52-week low of $0.28 and a 52-week high of $4.30. The company has a 50 day moving average of $0.34 and a 200 day moving average of $0.81. The company has a market capitalization of $8.82 million, a P/E ratio of -0.38 and a beta of 1.95.

Wall Street Analyst Weigh In

VYNE has been the subject of a number of recent research reports. BTIG Research downgraded shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, July 31st. Lifesci Capital cut shares of VYNE Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 30th. Weiss Ratings reissued a “sell (e+)” rating on shares of VYNE Therapeutics in a report on Wednesday, October 8th. Finally, HC Wainwright cut shares of VYNE Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, July 30th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $6.25.

Hedge Funds Weigh In On VYNE Therapeutics

A number of institutional investors have recently modified their holdings of the business. Boothbay Fund Management LLC acquired a new position in shares of VYNE Therapeutics in the 2nd quarter valued at $176,000. Adage Capital Partners GP L.L.C. increased its holdings in shares of VYNE Therapeutics by 87.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after acquiring an additional 300,000 shares during the period. Finally, Jane Street Group LLC acquired a new position in shares of VYNE Therapeutics in the 2nd quarter valued at $206,000. 83.78% of the stock is owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.